A new seed round will support the launch of CUE1, a novel therapy with a waiting list of more than 6000 people.
Imperial medtech startup Charco Neurotech raises $10 million
More From the Press
Parkinson’s Insights share our latest clinical publication and transitional journey towards Class IIa medical device certification
Charco Neurotech prepares to relaunch CUE1+ following trial findings and medical device certification. Read article
Read more
Parkinson’s UK share our latest clinical publication
Results from a clinical trial of CUE1+, a chest-mounted device, has shown it’s well tolerated by people with…
Read moreCharco Neurotech announces publication of a pilot RCT, with data highlighting that the CUE1+ is safe, well tolerated, with encouraging signals for motor symptom relief in people with Parkinson’s
A double-blind, placebo-controlled study of 50 people with Parkinson’s, published in Parkinson’s Disease, part of the Nature Portfolio, is the first…
Read more